FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116633404> ?p ?o ?g. }

• W2116633404 endingPage "842" @default.
• W2116633404 startingPage "834" @default.
• W2116633404 abstract "In Brief BACKGROUND: Opioid-induced side effects, such as pruritus, nausea, and vomiting are common and may be more debilitating than pain itself. A continuous low-dose naloxone infusion (0.25 μg/kg/h) ameliorates some of these side effects in many but not all patients without adversely affecting analgesia. We sought to determine the optimal dose of naloxone required to minimize opioid-induced side effects and to measure plasma morphine and naloxone levels in a dose escalation study. METHODS: Fifty-nine pediatric patients (24 male/35 female; average age 14.2 ± 2.2 years) experiencing moderate to severe postoperative pain were started on IV patient-controlled analgesia morphine (basal infusion 20 μg/kg/h, demand dose 20 μg/kg, 5 doses/h) and a low-dose naloxone infusion (initial cohort: 0.05 μg/kg/h; subsequent cohorts: 0.10, 0.15, 0.25, 0.40, 0.65, 1, and 1.65 μg/kg/h). If 2 patients developed intolerable nausea, vomiting, or pruritus, the naloxone infusion was increased for subsequent patients. Dose/treatment success occurred when 10 patients had minimal side effects at a naloxone dose. Blood samples were obtained for measurement of plasma morphine and naloxone levels after initiation of the naloxone infusion, processed, stored, and measured by tandem mass spectrometry with electrospray positive ionization. RESULTS: The minimum naloxone dose at which patients were successfully treated with a <10% side effect/failure rate was 1 μg/kg/h; cohort size varied between 4 and 11 patients. Naloxone was more effective in preventing pruritus than nausea and vomiting. Concomitant use of supplemental medicines to treat opioid-induced side effects was required at all naloxone infusion rates. Plasma naloxone levels were below the level of assay quantification (0.1 ng/mL) for infusion rates ≤0.15 μg/kg/h. At rates >0.25 μg/kg/h, plasma levels increased linearly with increasing infusion rate. In each dose cohort, patients who failed therapy had comparable or higher plasma naloxone levels than those levels measured in patients who did not fail treatment. Plasma morphine levels ranged between 3.52 and 172 ng/mL, and >90% of levels ranged between 10.2 and 61.6 ng/mL. Plasma morphine levels were comparable between patients who failed therapy and those patients who achieved symptom control. CONCLUSIONS: Naloxone infusion rates ≥1 μg/kg/h significantly reduced, but did not eliminate, the incidence of opioid-induced side effects in postoperative pediatric patients receiving IV patient-controlled analgesia morphine. Patients who failed therapy generally had plasma naloxone and morphine levels that were comparable to those who had good symptom relief suggesting that success or failure to ameliorate opioid-induced side effects was unrelated to plasma levels. Published ahead of print September 2, 2011" @default.
• W2116633404 created "2016-06-24" @default.
• W2116633404 creator A5015341987 @default.
• W2116633404 creator A5019400764 @default.
• W2116633404 creator A5040038992 @default.
• W2116633404 creator A5065984955 @default.
• W2116633404 creator A5079049150 @default.
• W2116633404 creator A5079888696 @default.
• W2116633404 creator A5086332857 @default.
• W2116633404 date "2011-10-01" @default.
• W2116633404 modified "2023-10-16" @default.
• W2116633404 title "The Optimal Dose of Prophylactic Intravenous Naloxone in Ameliorating Opioid-Induced Side Effects in Children Receiving Intravenous Patient-Controlled Analgesia Morphine for Moderate to Severe Pain" @default.
• W2116633404 cites W139116624 @default.
• W2116633404 cites W1485450669 @default.
• W2116633404 cites W1529134953 @default.
• W2116633404 cites W1964792919 @default.
• W2116633404 cites W1969391248 @default.
• W2116633404 cites W1970804412 @default.
• W2116633404 cites W1972241220 @default.
• W2116633404 cites W1974160877 @default.
• W2116633404 cites W1982214367 @default.
• W2116633404 cites W1987001885 @default.
• W2116633404 cites W2000000597 @default.
• W2116633404 cites W2003970587 @default.
• W2116633404 cites W2005482147 @default.
• W2116633404 cites W2014428356 @default.
• W2116633404 cites W2014786081 @default.
• W2116633404 cites W2014996264 @default.
• W2116633404 cites W2026173377 @default.
• W2116633404 cites W2026461987 @default.
• W2116633404 cites W2029521465 @default.
• W2116633404 cites W2051991575 @default.
• W2116633404 cites W2068016852 @default.
• W2116633404 cites W2084708008 @default.
• W2116633404 cites W2102262969 @default.
• W2116633404 cites W2121615260 @default.
• W2116633404 cites W2126484663 @default.
• W2116633404 cites W2137024631 @default.
• W2116633404 cites W2158491958 @default.
• W2116633404 cites W2161035367 @default.
• W2116633404 cites W2164039705 @default.
• W2116633404 cites W2181916489 @default.
• W2116633404 doi "https://doi.org/10.1213/ane.0b013e31822c9a44" @default.
• W2116633404 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4461032" @default.
• W2116633404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21890885" @default.
• W2116633404 hasPublicationYear "2011" @default.
• W2116633404 type Work @default.
• W2116633404 sameAs 2116633404 @default.
• W2116633404 citedByCount "46" @default.
• W2116633404 countsByYear W21166334042012 @default.
• W2116633404 countsByYear W21166334042013 @default.
• W2116633404 countsByYear W21166334042014 @default.
• W2116633404 countsByYear W21166334042015 @default.
• W2116633404 countsByYear W21166334042016 @default.
• W2116633404 countsByYear W21166334042017 @default.
• W2116633404 countsByYear W21166334042018 @default.
• W2116633404 countsByYear W21166334042019 @default.
• W2116633404 countsByYear W21166334042020 @default.
• W2116633404 countsByYear W21166334042021 @default.
• W2116633404 countsByYear W21166334042022 @default.
• W2116633404 countsByYear W21166334042023 @default.
• W2116633404 crossrefType "journal-article" @default.
• W2116633404 hasAuthorship W2116633404A5015341987 @default.
• W2116633404 hasAuthorship W2116633404A5019400764 @default.
• W2116633404 hasAuthorship W2116633404A5040038992 @default.
• W2116633404 hasAuthorship W2116633404A5065984955 @default.
• W2116633404 hasAuthorship W2116633404A5079049150 @default.
• W2116633404 hasAuthorship W2116633404A5079888696 @default.
• W2116633404 hasAuthorship W2116633404A5086332857 @default.
• W2116633404 hasBestOaLocation W21166334041 @default.
• W2116633404 hasConcept C126322002 @default.
• W2116633404 hasConcept C170493617 @default.
• W2116633404 hasConcept C199360897 @default.
• W2116633404 hasConcept C2775962371 @default.
• W2116633404 hasConcept C2777389121 @default.
• W2116633404 hasConcept C2778750930 @default.
• W2116633404 hasConcept C2780580376 @default.
• W2116633404 hasConcept C2780852908 @default.
• W2116633404 hasConcept C2781063702 @default.
• W2116633404 hasConcept C3454156 @default.
• W2116633404 hasConcept C41008148 @default.
• W2116633404 hasConcept C42219234 @default.
• W2116633404 hasConcept C71924100 @default.
• W2116633404 hasConceptScore W2116633404C126322002 @default.
• W2116633404 hasConceptScore W2116633404C170493617 @default.
• W2116633404 hasConceptScore W2116633404C199360897 @default.
• W2116633404 hasConceptScore W2116633404C2775962371 @default.
• W2116633404 hasConceptScore W2116633404C2777389121 @default.
• W2116633404 hasConceptScore W2116633404C2778750930 @default.
• W2116633404 hasConceptScore W2116633404C2780580376 @default.
• W2116633404 hasConceptScore W2116633404C2780852908 @default.
• W2116633404 hasConceptScore W2116633404C2781063702 @default.
• W2116633404 hasConceptScore W2116633404C3454156 @default.
• W2116633404 hasConceptScore W2116633404C41008148 @default.
• W2116633404 hasConceptScore W2116633404C42219234 @default.
• W2116633404 hasConceptScore W2116633404C71924100 @default.
• W2116633404 hasIssue "4" @default.
• W2116633404 hasLocation W21166334041 @default.

• next